TD Cowen raised the firm’s price target on Medpace (MEDP) to $462 from $356 and keeps a Sell rating on the shares. The firm saidthe company’s preliminary 2026 outlook as well as cancels being “well-behaved” and pre-backlog pipeline value growth of 30% year-over-year is a positive sign for the company’s fundamental outlook.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MEDP: